Search results | hypertension

Reports

Hypertension Partnering

The Hypertension Partnering provides understanding and access to the hypertension partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

M&A rumor: Is Covidien buying hypertension treatment firm Maya Medical?

The intense competition for the best treatment of runaway hypertension looks like it’s about to heat up

M&A: Medtronic will likely acquire another hypertension therapy firm

Medtronic CEO Omar Ishrak has signaled that executives have to meet his strict criteria on M&A deals, but he may have to relax the rule in one product group

Arbor Pharma looking for an acquisition and merger partner

Arbor Pharmaceuticals LLC is allegedly exploring a potential acquisition and merger partner that could bring in more than $1 billion, according to people who are close to the situation.

Cardiovascular partnering – recent market research analysis 2009-2014

Recent market research analysis by Current Agreements shows that partnering in the last decade has seen an increase in cardiovascular deals with an increase in modern diagnostic technology development.

SciClone Pharmaceuticals: Big biotech partnering trends 2009-2014

SciClone Pharmaceuticals is a US based specialty company. The company focusses its efforts to widen its portfolio in China by in-licensing and acquiring rights to marketed products.

Ophthalmics partnering – recent deals analysis 2009-2014

Deal analysis by Current Agreements  shows that ophthalmics dealmaking activity has been steady with an average of 68 deals signed since 2009.

Astellas

Astellas is a top pharmaceutical company based in Tokyo, Japan

Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan

United Therapeutics: Passionate about pulmonary diseases

United Therapeutics is a biotechnology company developing medications for cardiopulmonary indications; the company has four major products in global circulation and is developing a promising pipeline of further products.

Actelion: Conducting sophisticated partnerships only

Actelion is a Switzerland based biopharmaceutical company discovering, developing and commercializing products for unmet medical needs.

Events

Sorry, your search returned no results.


Deals

Takeda pharma deals Arbor for hypertension drug

Takeda Pharmaceutical pharma deals Arbor Pharmaceuticals  Arbor for a licensing, development and commercialization agreement.

M&A rumor: Is Covidien buying hypertension treatment firm Maya Medical?

The intense competition for the best treatment of runaway hypertension looks like it’s about to heat up

M&A: Medtronic will likely acquire another hypertension therapy firm

Medtronic CEO Omar Ishrak has signaled that executives have to meet his strict criteria on M&A deals, but he may have to relax the rule in one product group

Pfizer enters agreement with Ergonex Pharma to acquire investigational treatment for pulmonary arterial hypertension

Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension (PAH). Under the terms of the agreement, Pfizer will support the completion of the ongoing Phase 2 trial for terguride and will have exclusive worldwide rights excluding Japan to commercialize terguride for the treatment of PAH. Ergonex will be more »

Ascendis completes $60 million series D financing

Ascendis Pharma announced the successful completion of a $60 million Series D financing

Bayer and Merck sign a pharma deal for $2.1 billion

Bayer and Merck & Co also agreed to enter into a strategic pharma deal collaboration in the area of cardiovascular diseases with a focus on sGC modulation.

CVRx in $29.6 million equity financing

CVRx has completed a private equity financing totaling $29.6 million.

AstraZeneca big pharma deals Par Pharmaceutical for Atacand supply and distribution

AstraZeneca enters big pharma deals with Par Pharmaceutical Companies for an exclusive U.S. supply and distribution agreement in which Par will distribute the authorized generic version of AstraZeneca’s Atacand.

Boston Scientific jumps in renal market with m&a of Vessix Vascular

Boston Scientific Corporation signed a definitive M&A agreement with Vessix Vascular with a view to extend its reach into the strategically critical renal denervation market

Big Pharma Boehringer Ingelheim resolves allegations against improper promotion of Aggrenox

Boehringer Ingelheim Pharmaceuticals, a top big pharma company,  has agreed to pay $95 million to resolve allegations relating to the improper promotion of the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease (COPD) drugs Atrovent and Combivent, and the hypertension drug Micardis, the Justice Department announced today